title: EPLIN-α expression in human oesophageal cancer and its impact on cellular aggressiveness and clinical outcome.
abstract: BACKGROUND
  Epithelial protein lost in neoplasm-α (EPLIN-α) is a cytoskeletal protein whose expression is often lost or is aberrant in cancerous cells and tissues and whose loss is believed to be involved in aggressive phenotype. Our current study examined this molecule in human oesophageal tissues and investigated the cellular impact of EPLIN-α on oesophageal cancer cells.
  
  
  METHODS
  Expression of the EPLIN-α transcript in human oesophageal tissues (tumour, paratumour and normal) was determined using the Quantitative Polymerase Chain Reaction (Q-PCR) method. In vitro models, including invasion, cellular migration (Electrical Cell substrate Impedance Sensing based method), cell growth and matrix adhesion assays were employed in order to assess the biological influence of EPLIN-α expression on KYSE150 oesophageal cancer cells.
  
  
  RESULTS
  EPLIN-α expression was lower in tumour tissues compared to normal tissue. Grade 3-5 tumours had slightly lower levels of EPLIN-α compared with those of grade 2. Patients who died of oesophageal cancer had significantly lower levels of EPLIN-α compared to those who remained disease-free (p=0.022). Lower levels of EPLIN-α transcript were seen in advanced oesophageal cancer, including TNM stages 2 to 4. Reduced EPLIN-α expression was associated with lymphatic metastasis and local advanced T-stage cancer, including T2-T4. Forced expression of EPLIN-α in oesophageal cancer cells rendered cells less invasive and reduced their cell growth rate in vitro.
  
  
  CONCLUSIONS
  Our study suggests that EPLIN-α is expressed at lower levels in oesophageal cancer tissues. This down-regulation has a prognostic value. Together with the findings that EPLIN-α inhibits cellular growth and invasion, we conclude that EPLIN-α is a tumour suppressor of oesophageal cancer.
authors.affiliation: Metastasis and Angiogenesis Research Group, Cardiff University School of Medicine, Cardiff, UK.
authors.forename: Yinan
authors.initials: Y
authors.lastname: Liu
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Sanders
authors.forename: Lijian
authors.initials: L
authors.lastname: Zhang
authors.forename: Wen G
authors.initials: WG
authors.lastname: Jiang
mesh_terms: D001483:Base Sequence; D002454:Cell Differentiation; D002455:Cell Division; D003598:Cytoskeletal Proteins / Q000235:genetics / Q000378:metabolism* / Q000502:physiology; D017931:DNA Primers; D004938:Esophageal Neoplasms / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D012333:RNA, Messenger / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016896:Treatment Outcome
chemical_list: D003598:Cytoskeletal Proteins; D017931:DNA Primers; C403263:LIMA1 protein, human; D012333:RNA, Messenger